Avalo Therapeutics (AVTX) Assets Average (2016 - 2025)
Historic Assets Average for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to $125.8 million.
- Avalo Therapeutics' Assets Average rose 2172.59% to $125.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.8 million, marking a year-over-year increase of 2172.59%. This contributed to the annual value of $85.9 million for FY2024, which is 21590.32% up from last year.
- Per Avalo Therapeutics' latest filing, its Assets Average stood at $125.8 million for Q3 2025, which was up 2172.59% from $132.6 million recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Assets Average ranged from a high of $144.6 million in Q1 2025 and a low of $25.1 million during Q4 2023
- Over the past 5 years, Avalo Therapeutics' median Assets Average value was $71.1 million (recorded in 2022), while the average stood at $74.1 million.
- Its Assets Average has fluctuated over the past 5 years, first plummeted by 6017.88% in 2022, then skyrocketed by 39576.63% in 2024.
- Avalo Therapeutics' Assets Average (Quarter) stood at $87.8 million in 2021, then tumbled by 60.18% to $35.0 million in 2022, then dropped by 28.11% to $25.1 million in 2023, then surged by 395.77% to $124.6 million in 2024, then grew by 1.0% to $125.8 million in 2025.
- Its Assets Average stands at $125.8 million for Q3 2025, versus $132.6 million for Q2 2025 and $144.6 million for Q1 2025.